Related Experiment Video

Updated: Nov 28, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.0K

Breast Cancer Resistance Protein: A Potential Therapeutic Target for Cancer

Sonali Mehendale-Munj1, Shivangi Sawant1

  • 1Department of Pharmaceutical Chemistry, Vivekanand Education Society's College of Pharmacy, Hashu Advani Memorial Complex, Behind Collector's Colony, Chembur (E), Mumbai 400074, Affiliated to University of Mumbai, Maharashtra, India.

Current Drug Targets
|November 27, 2020
PubMed

Insights

Breast Cancer Resistance Protein (BCRP) causes multidrug resistance by expelling chemotherapy drugs, leading to treatment failure. Understanding BCRP

Area of Science:

  • Molecular Biology
  • Pharmacology
  • Oncology

Background:

  • Breast Cancer Resistance Protein (BCRP) is an ATP-binding cassette (ABC) superfamily half-transporter.
  • BCRP (encoded by ABCG2) is crucial for xenobiotic and toxin protection.
  • It mediates multidrug resistance (MDR) by effluxing antineoplastic drugs.

Purpose of the Study:

  • To elucidate the role of BCRP in cancer multidrug resistance.
  • To highlight the impact of BCRP expression on cancer therapy outcomes.
  • To emphasize the physiological significance of BCRP in xenobiotic transport.

Main Methods:

  • Review of existing literature on BCRP function and expression.
  • Analysis of BCRP's role in drug efflux mechanisms.
  • Examination of BCRP expression patterns in various cancers and stem cells.

Main Results:

  • BCRP actively expels numerous chemotherapeutic agents, contributing to MDR.
  • High BCRP expression is observed in brain, liver, lung cancers, AML, and stem cells.
  • BCRP's efflux function directly impacts the efficacy of cancer treatments.

Conclusions:

  • BCRP is a significant factor in chemotherapy resistance and treatment failure.
  • Understanding BCRP regulation is critical for overcoming MDR.
  • Targeting BCRP may improve therapeutic outcomes in BCRP-expressing cancers.
Keywords:
ABCG2BCRPBCRP inhibitorsmitoxantrone-resistance proteinmultidrug resistancetransporter

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.4K
Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

6.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K